Capricor Therapeutics, Inc. (CAPR) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $7.08. The rating moved from Oversold to Neutral on August 18, 2026.

• Public ratingNeutral (as of August 19, 2026)
• Last close$7.08
• Last changeMoved from Oversold to Neutral on August 18, 2026
• SectorHealthcare
• IndustryBiotechnology

AI analysis

Capricor Therapeutics, Inc. is a small-cap, pipeline-driven biotechnology company centered on cell-therapy candidates that have binary clinical/regulatory catalysts. The company lacks meaningful product revenue and depends on capital markets or strategic transactions to fund development, creating dilution and runway uncertainty. Upside is contingent on positive clinical readouts, partnering or M&A interest, and favorable manufacturing/reimbursement outcomes. Downside stems from trial setbacks, financing needs, regulatory delays, and limited liquidity. Near-term movement is likely driven by clinical milestones, news flow, and macro sentiment toward speculative biotech stocks.

Key factors

• Pipeline focus on cell therapy (CAP-1002) addressing rare and high-unmet-need indications with potential for high-value outcomes if clinical data is positive
• Small-cap biotech with limited or no meaningful product revenues; financial runway and cash position drive near-term valuation
• Recent sector tailwinds for biologics and CDMO demand could indirectly support partner interest or strategic transactions
• Potential for partnership, licensing, or M&A interest if clinical data or regulatory progress shows promise
• Market environment is cautiously risk-on, which can support speculative biotech flows in the short term but may reverse on macro headlines

Risks

• Clinical trial failure, delayed readouts, or weak efficacy/safety data for lead programs
• High likelihood of dilutive financing to fund operations, pressuring equity holders
• Regulatory uncertainty and long approval timelines for cell therapies
• Limited commercialization experience and infrastructure absent a partner
• Low liquidity and high share-price volatility common to microcap biotechs
• Reimbursement, manufacturing scale-up, and COGS risks that could limit commercial upside

Latest MarketMoodz coverage

• Moderna, Capricor Lead Biotech Movers on FDA Shakeups and HOPE-3 Data2026-03-09

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.